TG Therapeutics Inc

NASDAQ:TGTX   4:00:00 PM EDT
15.21
-0.36 (-2.31%)
4:26:37 PM EDT: $15.21 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.35B
Current PE185.35
Forward PE N/A
2yr Forward PE 33.8
See more stats
Estimates Current Quarter
Revenue$54.57 Million
Adjusted EPS-$0.05
See more estimates
10-Day MA$15.52
50-Day MA$15.53
200-Day MA$14.52
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 264

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.